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Objective: Despite well-documented good early results and benefits of endoluminal stent graft repair of abdominal aortic
aneurysm (J Vasc Surg 2002;35:1137-44.)(AAA), the long-term outcome of this method of treatment remains
uncertain. In particular, concern exists that late effectiveness and durability are inferior to that of open repair. To
determine the incidence and causes of clinical failures of endovascular AAA repair, a 7-year experience with 362 primary
AAA endografts was reviewed.
Methods: Clinical failures were defined as deaths within 30 days of the procedure, conversions (early and late) to open AAA
repair, AAA rupture after endoluminal treatment, or AAA sac growth of more than 5 mm in maximal diameter despite
endograft repair. Endoleak status per se was not considered unless it resulted in an adverse event. If clinical problems
arose but could be corrected with catheter-based therapies or limited surgical procedures, thereby maintaining the
integrity of successful stent graft treatment of the AAA, such cases were considered as primary assisted success and not
classified as clinical failures.
Results: The average follow-up period was 1.5 years. Six deaths (1.6%) occurred after the procedure, all in elderly patients
or patients at high risk. Five patients (1.4%) needed early conversion (immediate, 2 days) to open repair for access
problems or technical difficulties with deployment, resulting in an implantation success rate of 98.6%. Eight patients
(2.2%) underwent late conversion for a variety of problems, including AAA expansion (n 4), endograft thrombosis (n
1), secondary graft infection (n  2), and rupture at 3 years (n  1). Rupture occurred in an additional two patients for
a total incidence rate of 0.8%. AAA sac growth of greater than 5 mm was observed in 20 patients (5.6%), four of whom
have undergone successful catheter-based treatments to date. Overall, 39 patients (10.7%) needed catheter-based (n 45)
or limited surgical (n  4) reinterventions for a variety of late problems that were successful in 92%.
Conclusion: In our 7-year experience, one or more clinical failures of endovascular AAA repair were observed in 31
patients (8.3%). Reinterventions were necessitated in a total of 10.7% of patients but were usually successful in
maintaining AAA exclusion and limiting AAA growth. These results emphasize that endovascular repair provides good
results and many benefits for most properly selected patients but is not as durable as standard open repair. (J Vasc Surg
2002;35:1137-44.)
Standard open repair of abdominal aortic aneurysm
(AAA) has been well documented as an effective and dura-
ble treatment that can be performed with highly acceptable
morbidity and mortality rates in many experienced cen-
ters.1-4 However, the risk of operation is reported as con-
siderably higher (5% to 10% mortality rate) in numerous
population-based reports, and many patients at high risk
are often denied open surgical repair.5-8 Major complica-
tions of open repair are experienced by at least 15% to 30%
of patients after conventional open graft repair, and mor-
bidity and mortality rates increase substantially in elderly
patients or in those patients with pulmonary, cardiac, or
renal comorbities.9-11 In addition, long hospital stays, ex-
tensive rehabilitation, and prolonged convalescence are
commonplace, and many elderly or frail patients never
quite return to baseline function.12 Furthermore, tradi-
tional open repair can lead to prolonged intensive care
stays, extended hospitalizations, and other excessive re-
source use, which can become a strain fiscally to many
hospitals in this current cost-conscious era.13,14
Since the introduction of endoluminal repair in
1991,15 this technique has been eagerly accepted and used
with rapidly increasing frequency in a growing number of
centers within recent years. The potential advantages of
reduced risk, quicker recovery, and possibly diminished
care costs have generated intense interest on the part of
patients, physicians, and industry alike. In September 1999,
two devices were granted Food and Drug Administration
(FDA) approval, and several devices currently in clinical
trials will likely become commercially available within the
next several years.
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Review of the current literature clearly documents the
early feasibility and efficacy of endovascular repair of
AAA.16-21 However, some reports of mid-term experience
have described a somewhat disturbing incidence of compli-
cations related to device failures, endoleaks, or other exam-
ples of treatment shortcoming, including continued AAA
growth or even rupture despite endoluminal therapy.22-27
For these reasons, uncertainty remains regarding the
long-term effectiveness of endoluminal AAA repair and its
proper role in the management of patients with AAA. In
particular, debate continues as to whether or not younger
patients at good risk should be treated in this fashion or
whether small aneurysms should be treated at an earlier
interval in a more aggressive approach with stent grafts. To
examine outcome data that might impact decisions on
these issues, we reviewed a 7-year experience with 362
primary AAA endografts to determine the frequency of
beneficial outcome and the incidence and causes of clinical
failures of endovascular repair.
METHODS
Endograft repair of aneurysms or other vascular lesions
began at the Massachusetts General Hospital in January
1994. Retrospective review up to January 2001 identified a
total of 424 endovascular graft procedures during this
7-year experience. Sixty-two patients who underwent en-
doluminal repair of thoracic, iliac, or subclavian aneurysms
or exclusion of various anastomotic aneurysms were ex-
cluded from consideration, leaving a total of 362 consecu-
tive patients in whom treatment of primary AAAs by means
of stent grafts was performed. These 362 patients treated
during the 7-year period comprise the study group.
During the 7-year study period, a variety of endovascu-
lar grafts were used for aneurysm repair. Types and con-
figurations of the devices are detailed in Table I. Five
commercial endografts were used, as were a considerable
number of custom-made devices. The custom-made de-
vices were fabricated by our group from standard prosthetic
graft materials (woven Dacron or polytetrafluoroethylene)
and available intravascular stents (Gianturco Z-shaped
self-expanding stents, Cook, Inc, Bloomington, Ind) as
described originally by Dake and coworkers28 and subse-
quently refined and improved by our group at the Massa-
chusetts General Hospital.29 These custom devices were
most often used in patients with anatomic or clinical char-
acteristics that made them ineligible for FDA protocols
with commercially manufactured endograft devices. These
features included short or ectatic (28 mm) proximal
necks, technically difficult or extensively aneurysmal iliac
anatomy, prohibitive operative risk, renal insufficiency, or
other adverse characteristics. In addition, custom devices
were implanted at various intervals during the 7-year study
period during which no FDA protocol studies were active
and thus no commercial devices available.
Patient selection for the procedure and decisions re-
garding devices used were based on radiologic imaging
studies. All patients underwent contrast enhanced comput-
erized tomography (CT) scans with 3.0-mm cuts and
three-dimensional reformatting. If initial measurements
and morphology of the aneurysm were favorable for endo-
vascular repair, multiplanar contrast angiography was per-
formed with a special catheter with radiopaque markers at
1-cm intervals (Cook, Inc) to allow for precise length
measurements and assessment of pelvic anatomy, particu-
larly in regard to device access.
All procedures were performed in the operating room.
The patients were prepared and draped for open repair in
case this became necessary. Most patients underwent epi-
dural anesthesia, and some needed general anesthesia.
Open common femoral artery exposure by means of small
groin incision was used for access. All patients underwent
systemic heparinization. Radiologic imaging was per-
formed with a high-quality portable C-arm fluoroscopic
unit with digital imaging and road mapping capability on a
radiolucent operating room table with movable top. A
completion angiogram was obtained in all patients. The
endoluminal device protocols were approved by the Insti-
tutional Review Board and Ethics Committee at the Mas-
sachusetts General Hospital.
Contrast enhanced CT scans and plain films were ob-
tained in all patients before discharge and again according
to protocol of the graft manufacturer, usually at 6 and 12
months and annually thereafter. If the CT scan was not
done at the Massachusetts General Hospital, then films
were obtained and reviewed by our staff.
Clinical failures of endovascular AAA repair were de-
fined as the following events: periprocedural death (30
days), early (30 days) or late conversion of endograft
repair to conventional open surgical repair, increase in
maximal AAA sac diameter of 5 mm or greater after en-
dograft exclusion, and AAA rupture after endoluminal an-
eurysm treatment. Endoleak status itself was not consid-
ered, unless the endoleak resulted in an adverse event such
as sac growth, conversion to open repair, or rupture.
Table I. Type and configuration of endograft device
MGH Gore Vanguard EVT AneuRx Cook Hybrid Total
ABI 59 50 29 38 76 10 5 267
AUNI 42 23 65
Tube 4 8 18 30
105 50 37 79 76 10 5 362
MGH, Massachusetts General Hospital custom-made grafts; hybrid, custom cuff with commercial endograft in combination; ABI, aortobiiliac; AUNI,
aortouniiliac.
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In addition to these clinical endpoints defining failure
of the endovascular repair, the frequency of subsequent
secondary interventions to investigate, repair, or otherwise
maintain the endograft was examined and the clinical prob-
lems needing such reintervention were documented. If
clinical problems arose but could be corrected with cathe-
ter-based therapies or limited surgical procedure, thereby
maintaining the integrity of successful stent graft treat-
ment, such cases were considered primary-assisted successes
and were not classified as clinical failures.
RESULTS
Eighty-three percent of treated patients were men. The
mean age was 74.6 years (range, 44 to 93 years), and the
mean AAA sac maximal diameter was 5.8 cm (range, 3.0 to
10.2 cm). Risk factors and comorbidities were typical of
patients undergoing vascular surgical procedures. Patient
demographics are displayed in Table II. The mean fol-
low-up period for the study group was 18 months, with
219 of the procedures (60.5%) performed within the last 2
years of the study period. Follow-up of more than 4 years
was available in nine patients, 66 patients had 3-year to
4-year follow-ups, and 68 patients had surveillance for 2 to
3 years after endograft repair.
In the 7-year experience, one or more clinical failures,
as defined previously, were observed in a total of 31 patients
(8.3%). Because some patients had more than one adverse
event denoting failure, the number of such events (n 42)
exceeded the number of patients (n 31) sustaining them.
Operative deaths. Six periprocedural deaths (1.5%)
occurred in the total of 362 AAA stent graft repairs (Table
III). One death occurred as the result of an acute myocar-
dial infarction on day 2 after implant in a cardiac patient at
high risk with known extensive coronary artery disease. The
procedure had been prolonged with a series of technical
deployment difficulties. Although eventually a technically
successful implant was achieved, in retrospect, more
prompt conversion to standard open repair would probably
have been advisable.
Diffuse atheroembolization was the cause of another
patient death after endoluminal stent graft placement. The
patient had severe multisystem organ failure. The family
refused dialysis and withdrew supportive care 2 weeks after
surgery.
One sudden early death occurred at home 5 days after
discharge and was presumed to be the result of rupture of a
large symptomatic AAA. A proximal attachment leak had
been suspected on predischarge CT scanning, but it had
been elected to observe this for possible spontaneous reso-
lution for a period of several weeks. Although no autopsy
was performed to confirm rupture, the patient apparently
had back and abdominal pain before collapse, and rupture
seems the likely cause.
Another patient became hypotensive in hospital 2 days
after apparently uneventful endoluminal repair. Emergency
CT scan showed a large retroperitoneal hematoma sugges-
tive of aneurysm rupture and a large endoleak believed to
possibly represent a type 2 or 4 endoleak. An endoleak of
indeterminate origin also had been observed on comple-
tion aortography after endograft implantation. Emergent
open repair was carried out, but the patient died of renal
and pulmonary insufficiency after a prolonged and complex
6-week postoperative course. In retrospect, possible vascu-
lar injury during endograft insertion and deployment was
suspected, although rupture may have been caused by
failure to exclude the AAA. The remaining two early deaths
occurred after early complications of endograft implanta-
tion, one involving acute thrombosis of a graft limb and
one iliac artery avulsion occurring on withdrawal of the
delivery system, resulting in severe retroperitoneal hemor-
rhage. A common thread in most of these cases was tech-
nical complications occurring in patients who were elderly,
fragile, and at high risk.
Early conversions. During the 7-year study period,
five patients (1.4%) needed early conversion to open repair
within the first 48 hours after the procedure (Table IV).
One of the patients had a 360-degree twist in the limbs of
Table IV. Early conversions (n  5)
Complication Operative correction Time
1 EVT limb twist Aortobiiliac graft Immediate
2 Failed insertions
(small iliac artery)
Aorto bifemoral graft Immediate
Aortic tube; aortofemoral
bypass
Immediate
1 Graft fell into sac Aortic tube Immediate
1 Early acute rupture Aortobiiliac graft 48 hours
Table II. Patient demographics
Total no. of patients 362
Age (years) 74.6 (44-93)
Male gender 302
Female gender 60
Average sac diameter (cm) 5.79 (3.0-10.2)
HTN 229 (63.6%)
CAD 208 (57.7%)
Tobacco use 188 (52.2%)
Diabetes 54 (15.0%)
Hyperlipidemia 117 (32.5%)
COPD 80 (22.2%)
Renal insufficiency 26 (7.2%)
HTN, Hypertension; CAD, coronary artery disease; COPD, chronic ob-
structive pulmonary disease.
Table III. Perioperative deaths (30 days)
Cause
MI after surgery
Massive atheroemboli
Died at home 5 days after discharge
Limb thrombosis-rhabdomyolysis
Avulsion EIA
Rupture 2 days after surgery
MI, Myocardial infarction; EIA, external iliac artery.
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an unsupported Ancure bifurcated device (Guidant, Santa
Clara, Calif) that could not be corrected. Two patients
treated early in our experience had small iliac arteries that
sustained severe traumatic injury during attempted passage
of large-caliber devices. In retrospect, these cases are exam-
ples of poor patient selection and inappropriate judgments
typical of an early “learning curve.” Another patient needed
immediate conversion when acute migration of the proxi-
mal attachment system occurred, resulting in the endograft
falling into the AAA sac. The final patient in this subgroup
had acute rupture of his aneurysm on postoperative day 2,
as already described in the previous section detailing
periprocedural deaths. Successful endograft implantation
was achieved in the remaining 357 patients, for an overall
procedural technical success rate of 98.6%.
Late conversions. Eight patients (2.2%) needed late
(30 days) conversion to standard open graft repair for a
variety of reasons (Table V). Conversions were performed
at a mean of 22 months after the original endograft proce-
dure (range, 2 to 36 months).
Conversion was believed to be necessary in four pa-
tients because of continued AAA growth. Endoleak was
present in all patients in this subgroup. Two patients had
persistent proximal type 1 attachment leak, one a persistent
type 2 leak from lumbar arteries, and one patient an acute
late type 3 endoleak caused by a fabric hole erosion in a
Vanguard endograft (Boston Scientific, Natick, Mass) im-
planted 6 months previously. The patient had done well,
with sac shrinkage and no endoleak, up to the 6-month
interval. The patient then was seen with sudden back pain,
and CT scanning showed a type 3 leak with acute sac
reexpansion. No rupture was found, however, at emergent
open operation. No conversion in our series was caused by
AAA sac growth without demonstrated endoleak (“endo-
tension”).
Two endoluminal grafts needed late conversion as the
result of graft infection. Both were presumed to be caused
by septicemic seeding of the endoluminal device. Although
these cases might conceivably be the result of primary
endograft infections, this is much less likely in our opinion.
One patient did well until 18 months after the original
procedure when he was seen at an outside facility with a
septic left knee joint. The patient underwent treatment
with drainage and antibiotics. Within several months, how-
ever, the patient returned again with bilateral septic knees
and septic shoulder joint. Blood cultures grew methicillin-
resistant Staphylococcus aureus. Again, the patient under-
went treatment with drainage and antibiotics. Despite this,
a left psoas muscle abscess developed that was drained
percutaneously. However, subsequent CT scans showed
communication with the endograft and the area of abscess.
Further, evidence of bone destruction developed of verte-
bral bodies lumbar 1 and 2. Subsequently, the patient
underwent a staged procedure of axillobifemoral bypass
grafting followed by removal of the infected endograft with
radical debridement of vertebral body osteomyelitis. The
patient was discharged from the hospital after a prolonged
hospital course. The second patient in whom infection
developed had a somewhat similar history. The patient did
well for 2.5 years after the original procedure, when he was
seen at an outside facility with a septic left knee joint. This
was attributed to infection of a subcutaneous vascular port
device, which had been inserted several years previously for
chronic treatment of hemochromatosis. The port was re-
moved, and antibiotic treatment was instituted. However,
several weeks later the patient returned with back pain. A
CT scan revealed an increase in the size of the AAA with an
inflammatory “rind” around it. On exploration, the graft
was found to be purulent. The patient underwent removal
of the endograft, aortic ligation, and extraanatomic bypass
with a good outcome.
One patient needed late conversion at 27 months for
acute thrombosis of the entire endograft, resulting in severe
lower extremity ischemia. Prior follow-up CT scans had
shown good AAA exclusion, with sac shrinkage and no
endoleak. However, kinking of the endograft limbs was
noted and believed attributable to the morphologic sac
changes caused by its shrinkage. The patient was asymp-
tomatic with intact pulses, so observation was elected.
Presumably, limb kinking increased, resulting in thrombo-
sis. Emergent axillobifemoral bypass grafting was per-
formed, with a satisfactory result.
The final patient in this subgroup underwent conver-
sion at 36 months for acute AAA rupture. This case will be
described subsequently.
Sac growth. In the series, follow-up CT imaging re-
vealed 20 patients with sac growth of the aneurysm of 5 mm
or greater, despite endoluminal repair of the AAA. All of
these patients had at least 90 days of follow-up. Of the 20
patients, four thus far have undergone successful treatment
with endovascular therapies. Further secondary interven-
tions are planned for most of the remaining patients with
AAA sac growth but had not yet been performed when the
study period was terminated. Such secondary procedures
included a variety of catheter-based therapies, such as in-
sertion of proximal or distal extender cuffs, branch or sac
embolization, or related interventions as deemed appropri-
Table V. Late conversions (n  8)
Complication Time Intervention
Sac Growth (4) 34 months Infrarenal aortounilateral
graft
6 months Infrarenal tube graft
18 months Infrarenal aortounilateral
graft
2 months Juxtarenal repair AAA
Infected grafts (2) 2.5 years Extraanatomic BPG
2 years Extraanatomic BPG;
resection of old aorta,
graft; insertion-PTFE
aortic graft; L1,2
corpectomy
Bilateral kink and
thrombosis (1)
26 months Extraanatomic BPG
Rupture (1) 3 years Infrarenal tube graft
BPG, Bypass graft; PTFE, polytetrafluoroethylene.
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ate with angiography or other diagnostic methods. None of
the patients with sac growth are symptomatic, and no
ruptures have occurred in this cohort.
Ruptures. During the 7-year experience, three pa-
tients (0.8%) are believed to have had AAA rupture after
their endoluminal repair. Two patients, one with unproven
but presumed rupture at home 5 days after surgery and the
second with in-hospital rupture on postoperative day 2
(possibly traumatic), have already been described previ-
ously in the sections detailing periprocedural deaths and
early conversions.
A final rupture occurred at 3 years after the original
endovascular procedure, which was a tube endoprosthesis.
The patient had undergone five interval CT scans that had
shown no leak and a decrease in maximal AAA diameter
from 5 to 3.6 cm. Shortly after the most recent follow-up
CT scan, the patient was seen acutely with abdominal and
back pain. Emergency CT scan showed a large endoleak
and acute reexpansion of the AAA sac to the original 5-cm
diameter, with an adjacent retroperitoneal hematoma. At
emergency operation, acute detachment of the distal stent
attachment mechanism of the tube endograft was found,
with the distal endograft lying free in the AAA sac. We
presumed the shrinking AAA sac wall had become atretic
and ruptured when acutely repressurized. The patient sur-
vived operative conversion to open repair. After a pro-
longed hospitalization, the patient was discharged to a
rehabilitation facility. Despite often extensive and emer-
gent operations needed for late conversion of endovascular
to open repairs, no deaths occurred as a result of such
procedures in our series.
Secondary reinterventions. A variety of problems af-
ter endograft repair were identified at various intervals
during clinical and radiologic postimplant follow-up sur-
veillance (Table VI). These included persistent primary
endoleaks, late secondary leaks, instances of graft migra-
tion, kinking, or thrombosis, and other problems that were
believed to threaten endoluminal repair and expose the
patient to possible conversion or rupture or both. For this
reason, reinterventions were believed necessary.
During the 7-year study period, 39 patients (10.7%)
needed a total of 49 secondary procedures. The vast major-
ity of these were catheter-based reinterventions (n  45),
including reballooning, insertion of additional vascular
stents in native vessels, proximal or distal extensions of the
original stent graft device, embolization of branch vessels
or the AAA sac itself, or similar related procedures. These
were judged clinically effective in correcting or eliminating
the problem needing reintervention in 92% of the 39
patients. Patients who underwent such success reinterven-
tions were not classified as having clinical failures but rather
as having assisted-primary successes.
DISCUSSION
This series summarizes the data from our initial 7-year
experience with 362 patients with AAAs treated with en-
doluminal stent graft repair at the Massachusetts General
Hospital. Our results confirm a growing number of reports
from other centers that clearly document that endovascular
AAA repair is safe and can be successfully performed in
patients with suitable anatomy.16-21 As in our series, the
implant success in most centers is now approaching 98% to
99%, and this and other outcome parameters are likely to
further improve with second-generation and third-genera-
tion devices.30 In addition to low mortality and only a 1%
early conversion rate, our results document quite effective
treatment of the AAA relative to its anticipated natural
history, albeit with a relatively short 1.5-year mean fol-
low-up period. The AAA has remained stable in size or
actually diminished in maximal diameter in 94% of cases,
and serious late problems, such as conversion to open repair
(2.2%) and AAA rupture (1%), remain infrequent.
The less invasive characteristics of endoluminal repair
are clearly reflected by the low morbidity and mortality
rates reported in most series. The mortality rate of our series
was 1.6%. Although this rate is not significantly different
from results from several high-volume single institution
reports involving traditional open repair, we believe many
of the patients in our series who underwent endoluminal
repair were truly high-risk patients, often with advanced
cardiopulmonary problems or other comorbid problems,
who would very likely have had considerably higher mor-
tality rates if treated with conventional open operation.
This contention remains unproven, of course, because no
truly randomized prospective data exist in this regard. It is
worthwhile emphasizing that most of the deaths in this
series occurred after technical difficulties with the endovas-
cular repair, usually in elderly, fragile patients with adverse
challenging anatomic features. We believe this underscores
the need for careful patient selection and adherence to
accepted anatomic selection criteria.
Although endoleak, defined as a failure to totally ex-
clude the AAA from continued perfusion and pressuriza-
tion, remains a potential concern, we have not regarded this
as a mode of clinical failure unless an adverse sequelae, such
as continued AAA enlargement, AAA rupture, or other
problems, resulted. This position may be challenged by
some who believe that any demonstrated endoleak is a
criteria of failure. However, the patient is unaware of an
endoleak and not really concerned unless an undesirable
outcome results. Indeed, the clinical significance of en-
doleak remains uncertain and poorly understood.31-33 Sev-
eral studies have shown poor correlation between endoleak
Table VI. Problems needing secondary interventions
Problem n
Limb kinks/occlusions
Supported devices 4
Unsupported devices 11
Attachment leaks/slippage 11
Type II leaks with growth 11
Endotension 1
Type III leaks 5
Native vessel stenosis 2
Total 45
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and outcome, and many authorities believe the most com-
mon variety of endoleak, type 2 retrograde branch leak,
rarely causes clinical consequences.34-36 However, it
should be acknowledged that type I attachment leaks are
well recognized as more hazardous in terms of AAA en-
largement and rupture risk and that almost all type III
endoleaks will need some form of reintervention or conver-
sion. In addition, it should be noted that, in our series, all
four patients with AAA sac growth resulting in conversion
to open repair did have some type of endoleak, including
one patient with a type II branch leak alone. Conclusion
that endoleak is not a desirable or benign phenomenon
seems justified, but we do not regard its presence alone as
reliable prognostic predictor or a clear-cut indicator of
clinical failure of endoluminal repair.
Similarly, in our opinion, the need for limited second-
ary reinterventions should not be considered an indicator of
clinical failure of endoluminal AAA repair. As illustrated by
our series in which 11% of patients needed secondary
procedures, almost all catheter-based endovascular inter-
ventions rather than surgical procedures, the vast majority
(92%) were believed clinically successful in correcting the
presumed cause of sac growth or other clinical problems,
thereby maintaining the integrity and success of the en-
dograft repair. Similar success rates have been reported by
other investigators with respect to secondary interven-
tions.37,38 We believe the concept of primary-assisted suc-
cess, achieved by means of such limited reinterventions, is
valid and well accepted by patients as long as successful
endovascular treatment of their aneurysm can be main-
tained and major surgical repair avoided.
Although our reintervention rate was a relatively mod-
est 11%, our relatively short mean follow-up period of 18
months must be recognized. In the large European collab-
orative registry (Eurostar) experience of more than 1000
patients followed for 12 or more months, 18% have needed
secondary interventions at a mean follow-up interval of 20
months.37 With life-table analysis, cumulative freedom
from reintervention at 1, 3, and 4 years was 89%, 67%, and
62%. Thus, it appears reasonable to assume that secondary
interventions will be necessary at a cumulative rate of
approximately 10% per year. Similar Eurostar data have
emphasized the ongoing and cumulative incidence of both
late conversions and aneurysm rupture, noting cumulative
rates of approximately 2%/year for conversion to open
repair and a rupture risk of approximately 1%/year.39
The less invasive nature of the procedure, and the
generally good and beneficial early results of treatment,
clearly have made endovascular AAA repair an appealing, if
not compelling, therapeutic alternative to many patients
with AAA. Application of this method has increased rapidly
in many centers around the world, and many investigators
now urge more widespread use. Some regard it as the
procedure of choice for all AAAs that are anatomically
suitable and believe it is reasonable to use even in young
patients at good risk. Other advocates urge prophylactic
repair of small (5 cm) AAA, with the belief that the safer
and less invasive treatment would justify earlier treatment
and potentially improve long-term outcomes. However, we
believe our results, and mid-term results reported by other
investigators,40,41 should give some thoughtful concern in
this regard. The long-term effectiveness and durability of
endovascular repair clearly appears to be less than that
anticipated by most surgeons after standard open operative
repair.2,4 Although it must be acknowledged that conven-
tional surgical repairs are rarely subjected to the intense
scrutiny and postimplant surveillance common to endovas-
cular repair, nonetheless long-term effectiveness of en-
dograft repair as we now know cannot match the late
outcome and reliability of standard AAA operative repair.
Second-generation and third-generation devices may im-
prove endoluminal outcomes—most series to date, includ-
ing this report, are dominated by results of earlier, first-
generation endografts.42 This remains to be established,
however. In addition, future device advances and improve-
ments may reduce device structural failures and may enable
the endoluminal grafts to better accommodate to morpho-
logic AAA sac changes that have been recognized by many
authorities and that contribute to late failures by causing
endograft kinking, migration, component separation, and
other adverse consequences.43,44
We believe the clinical implications of our data are
several. First, endoluminal AAA repair has clearly been a
major advance. Its feasibility, safety, and generally good
early and mid-term results have been well shown in our
series and many other published reports. It appears partic-
ularly beneficial to more elderly patients at high risk, many
of whom may have previously been denied repair. In such
patients with suitable anatomy, it is reasonable and appro-
priate in our opinion to consider endovascular repair the
procedure of choice.45 However, it should be recognized
that the actual definition of “high-risk” is open to some
debate and not well defined in the literature. Similarly,
endoluminal repair seems advantageous in patients with a
“hostile” abdomen because of a variety of factors and also
an appealing and likely beneficial option in patients with
other unusual conditions that may cause technical difficul-
ties and challenges for conventional open repair, such as
paraanastomotic aneurysms after previous aortic surgery,
AAA in the presence of a horseshoe kidney, and AAA in
patients with prior renal transplants.
Secondly, because of current concerns related to device
structural stability and long-term reliability of this form of
repair, in our opinion, more widespread use of endografts
to repair small AAA cannot be supported.46 Similarly,
because endoleak, graft migration, and other failure modes
of endoluminal repair are much more frequent in patients
with adverse anatomy, this procedure should not be used
overaggressively in patients who do not have well-defined
appropriate aneurysmal anatomic features. This is particu-
larly true in patients at very high risk because the need for
conversion in these circumstances is likely to be associated
with truly excessive morbidity and mortality rates.39,47,48
One cannot overemphasize the importance of proper and
appropriate patient selection.
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Whether or not the procedure should be recommended
to younger patients at good risk remains unclear.45 Given
current technology, the increasing evidence of problems
related to device durability, more frequent need for rein-
terventions, and the small but definite continued risk of
AAA rupture, standard open repair still seems best for such
patients. It is mandatory, in our opinion, that vascular
surgeons properly inform patients of options, risks, and
potential benefits and shortcomings of both open and
endoluminal repair, so that they may make a truly informed
decision. Although many of these patients may still opt for
the less invasive repair even if fully advised, at least they will
be aware of the “tradeoffs” involved and perhaps better
committed to the need for repeated imaging and closer
long-term follow-up. Patient interest and demand for less
invasive treatment and societal pressures propelling
quicker, more simplified, and less costly procedures will
surely accelerate. Recognition of such forces serves to re-
emphasize the need for continued scientific scrutiny and
evaluation of endograft repair.
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DISCUSSION
Dr Frank LoGerfo (Boston, Mass). I just have one question
about endoleaks. I think you said that only sac growth, conversion,
or rupture were regarded as failures. You could have an endoleak,
have a pulsatile aneurysm, and it could essentially be no different
from the aneurysm without the endograft present, but that would
be considered a success. Is that correct?
Dr Jeffery Dattilo. That is correct. We think that the corre-
lation between leak and eventual abdominal aortic aneurysm
growth or rupture is unclear in the literature. This phenomenon, as
you know, is controversial. However, in cases with persistent
endoleak, we usually institute more frequent follow-up imaging
and clinical examinations.
Dr Gregorio Sicard (St Louis, Mo). It was a wonderful
presentation of one of the biggest experiences in the country, and
I will share with you some of our own experience, which is similar,
in St Louis.
I do have a question regarding your third conclusion. I think
we are getting used to saying endovascular repair cannot match
open repair. Obviously, without a randomized trial, we will not be
able to know the final answer. During the 7-year period you report
at the Massachusetts General Hospital, there were a large number
of open aneurysm repairs performed. Did you look at those num-
bers and compare them with endoluminal repair? Something that
has changed with endovascular repair is patient surveillance. Close
surveillance has become mandatory. We do not have that same
approach to open repair, and very few series have looked in a
longitudinal manner at the graft-related complications of open
repair. I will show you some data in my lecture that it is not as low as
we think it is. So, could you give us in that similar 7-year period the
graft-related complications with open repair, what was the follow-up,
and what is the follow-up surveillance protocol used in your service for
open repair? How often do you get CT scans to see if you have a
paraanastomotic aneurysm? Very few services do that. Thank you.
Dr Dattilo. Thank you, sir. Those are very interesting ques-
tions. To address the open aneurysm follow-up in our practice, we
have not involved the current open repairs into our database with
similar veracity as we do with the endoluminal repairs. We do
collect data on the open repairs, but as you well know, open repair
dates back to the 1960s and the data collection at that period of
time was not as large in scope as the endoluminal repair databases
that we are collecting now. I find that comparing those two groups
is going to be difficult, and we are not comparing in any kind of
randomized prospective way endoluminal or open repair at our
institution.
Dr Jack Cronenwett (Lebanon, NH). I have two questions.
First, did you find as you went through your study longitudinally
that the incidence rate of these complications decreased? As you
know, the Sydney group has reported in their sequential analysis
that they did not see the decrease in complications they expected,
perhaps because they expanded and enlarged the population and
the indications to include higher risk patients.
My second question relates to your incidence rate of reinter-
vention of approximately 10%. Could you tell us what that looks
like with life-table analysis? In other words, is it a relatively linear
curve over time, and if so, given that, you have done most of these
patients within the past year or 2, wouldn’t you expect that this
number is going to increase with longer follow-up?
Dr Dattilo. I am going to answer the second question first.
Clearly that is the case. Life table analysis would not offer much
value in our current data set. Perhaps with longer follow-up this
tool would be useful. Our data tend to mirror the Eurostar data,
which demonstrate that reinterventions on a cumulative basis are
approximately 8% to 10% per year. Does the incidence rate over
time change? For each subset of our clinical failures, it does not
correlate on a time-related basis, meaning two of our deaths were
in fact recent deaths. So that does not correlate with previous work
in the literature suggesting once you get over the steep learning
curve or rely upon device improvements you could obviate such
adverse outcomes.
JOURNAL OF VASCULAR SURGERY
June 20021144 Dattilo et al
